US FDA’s Marks Issues ‘Provocative’ Call For Target Gene Therapy Profile That Includes Costs
Executive Summary
CBER Director Peter Marks said recent leaps in gene therapy science have not been matched by more affordable manufacturing technology and that the field needs to set a cost-effectiveness target.